Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic

Convalescent plasma therapy holds promise as a transient treatment for COVID-19. Yet, blood products are important sources of HIV infection in low- and middle-income nations. Great care must be taken to prevent plasma therapy from fueling HIV epidemics in the developing world.

Detalles Bibliográficos
Autores principales: Ferreira, Leonardo M. R., Mostajo-Radji, Mohammed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338534/
https://www.ncbi.nlm.nih.gov/pubmed/32655899
http://dx.doi.org/10.1038/s41541-020-0209-2
Descripción
Sumario:Convalescent plasma therapy holds promise as a transient treatment for COVID-19. Yet, blood products are important sources of HIV infection in low- and middle-income nations. Great care must be taken to prevent plasma therapy from fueling HIV epidemics in the developing world.

Ejemplares similares